In 1986 Walaszek and co-workers demonstrated that taking D-Glucarate orally, in animals and humans, leads to a slow release of a substance that inhibits glucuronidase, an enzyme that thwarts the body’s efforts to rid itself of cancer causing substances known as carcinogens. Walaszek demonstrated that animals fed Glucarate have increased levels of a substance known as D-Glucaro-lactone, which inhibits glucuronidase. He looked at a model for breast cancer induction in rats, the animal used most frequently for breast cancer research. Rats given anthracene develop breast cancer, but if pre-treated with dietary Glucarate, tumor development was blocked in over 70%. When D-Glucarate was fed to the animals, the levels of estradiol (the form of estrogen that causes breast cancer) were decreased in the blood.

In summary, D-Glucarate lowers levels of glucuronidase, and thus allows the body to eliminate harmful carcinogens.

In animals fed various carcinogens the level of free carcinogen or carcinogen bound to DNA was measured in the blood. With calcium D-Glucarate, these levels were drastically reduced over a sustained period of time. Calcium D-Glucarate administration favors the elimination of carcinogens in the stool, an effect that lasts for several hours after a single low dose.

A principal clinical use of Calcium-D-Glucarate is in the prevention and reversal of "die-off" reactions by enhancing liver detoxification pathways.